Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Diarrhea. Found 6 abstracts

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016 Aug;39(4):340-5.   PMCID: PMC4177955
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2014 Oct;32(28):3103-10.
Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9.   PMCID: *
Held-Warmkessel J. Targeted cancer. These "smart weapons" hit cancer in novel ways. Nursing. 2008 Sep;38(9):26-32.
Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology. 2003 Oct;62(4):707-13.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Diarrhea

adverse effects Diarrhea chemically induced Female drug therapy Aged Middle Aged Male therapeutic use etiology Treatment Outcome antagonists & inhibitors Adult Neoplasms Antineoplastic Agents pathology Disease-Free Survival metabolism Adenocarcinoma administration & dosage Fatigue 80 and over Aged Drug Dose-Response Relationship Nausea analogs & derivatives Drug Administration Schedule Vomiting Area Under Curve Response Evaluation Criteria in Solid Tumors pharmacokinetics Patient Satisfaction Time Factors Vision Disorders Quality of Life Enoxaparin nursing Patient Education as Topic Oncologic Nursing Acne Vulgaris MAP Kinase Kinase 1 Drug Eruptions Cetuximab Biological Availability analysis Hypotension Dermatitis complications Radiotherapy Dosage Monoclonal Antibodies-Humanized CA-19-9 Antigen methods Maytansine Oral Administration US Gov't Support-PHS Monoclonal Antibodies psychology Nurse's Role Human Thromboembolism Adolescent Neoplasm Drug Resistance Thiazoles Ovarian Neoplasms Retreatment Anticoagulants Protein Kinase Inhibitors High-Energy Radiotherapy Antineoplastic Combined Chemotherapy Protocols blood Syndrome Platinum Compounds Radiation Dose-Response Relationship radiotherapy Protein-Tyrosine Kinases Stomatitis Gastrointestinal Hemorrhage Hemorrhage Cytokines Tablets Non-US Gov't Support Inhibitor of Apoptosis Proteins Camptothecin Hypertension Questionnaires chemistry Drug Delivery Systems secondary Hematuria Peritoneal Neoplasms Pharmaceutical Solutions secretion Fallopian Tube Neoplasms Dihydropyridines Survival Rate Immunoconjugates Bone Marrow Diseases Impotence Paronychia Urinary Incontinence Folate Receptor 1 Pancreatic Neoplasms Drug Monitoring Taxoids prevention & control MAP Kinase Kinase 2 Interstitial Lung Diseases Metabolic Clearance Rate Prostatic Neoplasms Young Adult Drug Interactions
Last updated on Friday, January 03, 2020